Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2012

Open Access 01-12-2012 | Research

Apoptotic activity in Libyan breast cancer

Authors: Jamela Boder, Fathi Abdalla, Mohamed Elfagieh, Abdelbaset Buhmeida, Yrjö Collan

Published in: World Journal of Surgical Oncology | Issue 1/2012

Login to get access

Abstract

Background

We evaluated the relationship of the apoptotic activity index (AI) and the standardized mitotic-apoptotic ratio (SMI/AI) with clinicopathological features and prognosis in Libyan female breast cancer (BC) patients. We then compared our results with corresponding results in Finnish and Nigerian female BC patients.

Methods

Histological samples of breast carcinoma from 130 patients were retrospectively studied: an estimation of the apoptotic activity per square millimeter (expressed as apoptotic activity index (AI)), and standardized mitotic-apoptotic ratio (SMI/AI) was made, and the results compared with the clinicopathological features and the patient’s survival.

Results

There was a statistically significant correlation between the AI and most of the clinicopathological features; the strongest association was observed for clinical stage lymph node (LN) status (P = 0.005). There were also correlations between AI and histological grade (P = 0.035), large tumor size (P = 0.011) and the clinical stage (P = 0.009). There were, however, prominent AI differences between Libyan, Nigerian and Finnish populations. The mean values of AI and SMI/AI in Libyan BC patients were 12.8 apoptotic figures per square millimeter and 2.8, respectively. The Libyan AI is slightly higher than in Nigeria, but much higher than in Finland. The differences between countries are seen throughout the samples as well as being present in certain subgroups. The survival analysis indicated that short survival time was associated with high apoptotic indices values and so can identify aggressive tumors and provide significant prognostic support. The cutoff (4 and 18 apoptosis/mm2) of AI might be applied as a quantitative criterion for Libyan BC to separate the patients into good, moderate and bad prognosis groups.

Conclusions

The results indicated that the differences in AI among the three countries may be due to the known variation in the distribution of genetic markers in these populations. Improvement in health care and introduction of screening programs, however, could be very helpful in the Libyan population.
Appendix
Available only for authorised users
Literature
1.
go back to reference van Slooten HJ, van de Vijver MJ, van de Velde CJ, van Dierendonck JH: Loss of Bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activity. Br J Cancer. 1998, 77: 789-796.PubMedCentralCrossRefPubMed van Slooten HJ, van de Vijver MJ, van de Velde CJ, van Dierendonck JH: Loss of Bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activity. Br J Cancer. 1998, 77: 789-796.PubMedCentralCrossRefPubMed
2.
go back to reference Koskinen PJ, Alitalo K: Role of myc amplification and overexpression in cell growth, differentiation and death. Semin Cancer Biol. 1993, 4: 3-12.PubMed Koskinen PJ, Alitalo K: Role of myc amplification and overexpression in cell growth, differentiation and death. Semin Cancer Biol. 1993, 4: 3-12.PubMed
4.
go back to reference Baak JP, Van Dop H, Kurver PH, Hermans J: The value of morphometry to classic prognosticators in breast cancer. Cancer. 1985, 56: 374-382.CrossRefPubMed Baak JP, Van Dop H, Kurver PH, Hermans J: The value of morphometry to classic prognosticators in breast cancer. Cancer. 1985, 56: 374-382.CrossRefPubMed
5.
go back to reference Ikpatt F: Nigerian breast cancer: prognostic value of histomorphometry. 2002, Turku: Annales Universitatis Turkuensis, 128- Ikpatt F: Nigerian breast cancer: prognostic value of histomorphometry. 2002, Turku: Annales Universitatis Turkuensis, 128-
6.
go back to reference Abdalla F, Boder J, Markus R, Hashmi H, Buhmeida A, Collan Y: Correlation of nuclear morphometry of breast cancer in histological sections with clinicopathological features and prognosis. Anticancer Res. 2009, 29: 1771-1776.PubMed Abdalla F, Boder J, Markus R, Hashmi H, Buhmeida A, Collan Y: Correlation of nuclear morphometry of breast cancer in histological sections with clinicopathological features and prognosis. Anticancer Res. 2009, 29: 1771-1776.PubMed
7.
go back to reference Boder J, Abdalla F, Elfageih M, Abusaa A, Alfagieh M, Buhmeida A, Collan Y: Breast cancer patients in Libya: comparison with European and central African patients. Oncology Letters. 2011, 2: 323-330.PubMedCentralPubMed Boder J, Abdalla F, Elfageih M, Abusaa A, Alfagieh M, Buhmeida A, Collan Y: Breast cancer patients in Libya: comparison with European and central African patients. Oncology Letters. 2011, 2: 323-330.PubMedCentralPubMed
8.
go back to reference van de Schepop HA, de Jong JS, van Diest PJ, Baak JP: Counting of apoptotic cells: a methodological study in invasive breast cancer. Clin Mol Pathology. 1996, 49: M214-M217.CrossRef van de Schepop HA, de Jong JS, van Diest PJ, Baak JP: Counting of apoptotic cells: a methodological study in invasive breast cancer. Clin Mol Pathology. 1996, 49: M214-M217.CrossRef
9.
go back to reference Lipponen P, Aaltomaa S, Kosma VM, Syrjanen K: Apoptosis in breast cancer as related to histopathological characteristics and prognosis. Eur J Cancer. 1994, 30A: 2068-2073.CrossRefPubMed Lipponen P, Aaltomaa S, Kosma VM, Syrjanen K: Apoptosis in breast cancer as related to histopathological characteristics and prognosis. Eur J Cancer. 1994, 30A: 2068-2073.CrossRefPubMed
10.
go back to reference Haapasalo H, Pesonen E, Collan Y: Volume corrected mitotic index (M/V-INDEX). The standard of mitotic activity in neoplasms. Pathol Res Pract. 1989, 185: 551-554.CrossRefPubMed Haapasalo H, Pesonen E, Collan Y: Volume corrected mitotic index (M/V-INDEX). The standard of mitotic activity in neoplasms. Pathol Res Pract. 1989, 185: 551-554.CrossRefPubMed
11.
go back to reference Haydon A: Adjuvant chemotherapy in colon cancer: what is the evidence?. Intern Med J. 2003, 33: 119-124.CrossRefPubMed Haydon A: Adjuvant chemotherapy in colon cancer: what is the evidence?. Intern Med J. 2003, 33: 119-124.CrossRefPubMed
12.
go back to reference Kinne DW: Primary therapy for limited breast cancer. Surgical techniques. Cancer. 1990, Suppl 9: 2129-2131.CrossRef Kinne DW: Primary therapy for limited breast cancer. Surgical techniques. Cancer. 1990, Suppl 9: 2129-2131.CrossRef
13.
go back to reference Heimann TM, Cohen RD, Szporn A, Gil J: Correlation of nuclear morphometry and DNA ploidy in rectal cancer. Dis Colon Rectum. 1991, 34: 449-454.CrossRefPubMed Heimann TM, Cohen RD, Szporn A, Gil J: Correlation of nuclear morphometry and DNA ploidy in rectal cancer. Dis Colon Rectum. 1991, 34: 449-454.CrossRefPubMed
14.
go back to reference Lei XY, Yao SQ, Zu XY, Huang ZX, Liu LJ, Zhong M, Zhu BY, Tang SS, Liao DF: Apoptosis induced by diallyl disulfide in human breast cancer cell line MCF-7. Acta pharmacologica Sinica. 2008, 29: 1233-1239.CrossRefPubMed Lei XY, Yao SQ, Zu XY, Huang ZX, Liu LJ, Zhong M, Zhu BY, Tang SS, Liao DF: Apoptosis induced by diallyl disulfide in human breast cancer cell line MCF-7. Acta pharmacologica Sinica. 2008, 29: 1233-1239.CrossRefPubMed
15.
go back to reference Li Y, Upadhyay S, Bhuiyan M, Sarkar FH: Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein. Oncogene. 1999, 18: 3166-3172.CrossRefPubMed Li Y, Upadhyay S, Bhuiyan M, Sarkar FH: Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein. Oncogene. 1999, 18: 3166-3172.CrossRefPubMed
16.
go back to reference Barderas R, Babel I, Casal JI: Colorectal cancer proteomics, molecular characterization and biomarker discovery. Proteomics Clin Appl. 2010, 4: 159-178.CrossRefPubMed Barderas R, Babel I, Casal JI: Colorectal cancer proteomics, molecular characterization and biomarker discovery. Proteomics Clin Appl. 2010, 4: 159-178.CrossRefPubMed
17.
go back to reference Ross JS, Torres-Mora J, Wagle N, Jennings TA, Jones DM: Biomarker-based prediction of response to therapy for colorectal cancer: current perspective. Am J Clin Pathol. 2010, 134: 478-490.CrossRefPubMed Ross JS, Torres-Mora J, Wagle N, Jennings TA, Jones DM: Biomarker-based prediction of response to therapy for colorectal cancer: current perspective. Am J Clin Pathol. 2010, 134: 478-490.CrossRefPubMed
18.
go back to reference Zheng WQ, Zhan RZ: Quantitative comparison of apoptosis to cell proliferation and p53 protein in breast carcinomas. Anal Quant Cytol Histol. 1998, 20: 1-6.PubMed Zheng WQ, Zhan RZ: Quantitative comparison of apoptosis to cell proliferation and p53 protein in breast carcinomas. Anal Quant Cytol Histol. 1998, 20: 1-6.PubMed
19.
go back to reference Zhang GJ, Kimijima I, Abe R, Watanabe T, Kanno M, Hara K, Tsuchiya A: Apoptotic index correlates to bcl-2 and p53 protein expression, histological grade and prognosis in invasive breast cancers. Anticancer Res. 1998, 18: 1989-1998.PubMed Zhang GJ, Kimijima I, Abe R, Watanabe T, Kanno M, Hara K, Tsuchiya A: Apoptotic index correlates to bcl-2 and p53 protein expression, histological grade and prognosis in invasive breast cancers. Anticancer Res. 1998, 18: 1989-1998.PubMed
20.
go back to reference Berardo MD, Elledge RM, de Moor C, Clark GM, Osborne CK, Allred DC: bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer. 1998, 82: 1296-1302.CrossRefPubMed Berardo MD, Elledge RM, de Moor C, Clark GM, Osborne CK, Allred DC: bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer. 1998, 82: 1296-1302.CrossRefPubMed
21.
go back to reference Ellis PA, Smith IE, Detre S, Burton SA, Salter J, A’Hern R, Walsh G, Johnston SR, Dowsett M: Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat. 1998, 48: 107-116.CrossRefPubMed Ellis PA, Smith IE, Detre S, Burton SA, Salter J, A’Hern R, Walsh G, Johnston SR, Dowsett M: Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat. 1998, 48: 107-116.CrossRefPubMed
22.
go back to reference Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN: Overview of resistance to systemic therapy in patients with breast cancer. Advan Exp Med Biol. 2007, 608: 1-22.CrossRef Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN: Overview of resistance to systemic therapy in patients with breast cancer. Advan Exp Med Biol. 2007, 608: 1-22.CrossRef
23.
go back to reference Mommers EC, van Diest PJ, Leonhart AM, Meijer CJ, Baak JP: Balance of cell proliferation and apoptosis in breast carcinogenesis. Breast Cancer Res Treat. 1999, 58: 163-169.CrossRefPubMed Mommers EC, van Diest PJ, Leonhart AM, Meijer CJ, Baak JP: Balance of cell proliferation and apoptosis in breast carcinogenesis. Breast Cancer Res Treat. 1999, 58: 163-169.CrossRefPubMed
24.
go back to reference Ikpatt F, Kuopio T, Erekul A, Collan Y: Apoptosis in breast cancer: Nigerian vs. Finnish material. Anal Quant Cytol Histol. 2002, 24: 73-80.PubMed Ikpatt F, Kuopio T, Erekul A, Collan Y: Apoptosis in breast cancer: Nigerian vs. Finnish material. Anal Quant Cytol Histol. 2002, 24: 73-80.PubMed
25.
go back to reference Jobling MA, Hurles M, Tyler-Smith C: Human evolutionary genetics Origin, peoples and disease. 2004, New York and Abingdon: Garland Science Jobling MA, Hurles M, Tyler-Smith C: Human evolutionary genetics Origin, peoples and disease. 2004, New York and Abingdon: Garland Science
26.
go back to reference McBride R, Hershman D, Tsai WY, Jacobson JS, Grann V, Neugut AI: Within-stage racial differences in tumor size and number of positive lymph nodes in women with breast cancer. Cancer. 2007, 110: 1201-1208.CrossRefPubMed McBride R, Hershman D, Tsai WY, Jacobson JS, Grann V, Neugut AI: Within-stage racial differences in tumor size and number of positive lymph nodes in women with breast cancer. Cancer. 2007, 110: 1201-1208.CrossRefPubMed
27.
go back to reference Dignam JJ: Differences in breast cancer prognosis among African-American and Caucasian women. CA Cancer J Clin. 2000, 50: 50-64.CrossRefPubMed Dignam JJ: Differences in breast cancer prognosis among African-American and Caucasian women. CA Cancer J Clin. 2000, 50: 50-64.CrossRefPubMed
28.
go back to reference Staunton MJ, Gaffney EF: Tumor type is a determinant of susceptibility to apoptosis. Am J Clin Pathol. 1995, 103: 300-307.PubMed Staunton MJ, Gaffney EF: Tumor type is a determinant of susceptibility to apoptosis. Am J Clin Pathol. 1995, 103: 300-307.PubMed
Metadata
Title
Apoptotic activity in Libyan breast cancer
Authors
Jamela Boder
Fathi Abdalla
Mohamed Elfagieh
Abdelbaset Buhmeida
Yrjö Collan
Publication date
01-12-2012
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2012
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-10-102

Other articles of this Issue 1/2012

World Journal of Surgical Oncology 1/2012 Go to the issue